文献速递认知障碍与痴呆

阿尔茨海默病何时开始?血浆Aβ42/40检测在Aβ-PET Centiloid 15时出现陡变,平均年龄66岁

When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 Years.
PubMed 文献 · Ann Neurol · 2026-01-26

该研究在4个国际队列1450名认知正常、轻度认知障碍或阿尔茨海默病痴呆参与者中,用两种免疫沉淀-质谱法检测血浆Aβ42/40,并结合Aβ-PET数据建模。结果显示血浆Aβ42/40在约15 Centiloid时快速变化,平均人群疾病年龄66岁,且比Aβ-PET异常早约2年;APOE等位基因携带者异常年龄和对应Centiloid水平更低。

要点

  • 血浆Aβ42/40在Aβ-PET约15 Centiloid时出现陡变,平均年龄66岁。
  • 血浆Aβ42/40平均比Aβ-PET异常早约2年出现。
  • APOE携带者血浆Aβ42/40异常年龄和对应Centiloid水平低于非携带者。

核心结论

  • 血浆Aβ42/40在Aβ-PET检测到斑块前不久呈现阶梯样变化,其异常年龄取决于APOE ε4携带状态。

研究设计与样本

  • 研究纳入4个国际队列共1450名参与者,诊断为认知正常、轻度认知障碍或阿尔茨海默病痴呆。
  • 采用两种高性能免疫沉淀-质谱法(WashU/C2N和Shimadzu)检测血浆Aβ42/40,并对Aβ-PET与血浆Aβ42/40联合数据进行自然史建模和轨迹分析。

主要发现

  • 两种检测均显示血浆Aβ42/40在约15 Centiloid时快速变化,平均人群疾病年龄为66岁。
  • 血浆Aβ42/40平均比Aβ-PET异常早约2年,并在临床前阿尔茨海默病起始时陡降至稳定水平。
  • APOE等位基因携带者血浆Aβ42/40异常的平均疾病年龄及对应Centiloid水平低于非携带者。
  • 结果与血浆Aβ42/40在Aβ-PET水平大于约14 Centiloid时降至稳态水平一致。

关键数值与推荐

  • 血浆Aβ42/40快速变化点约为15 Centiloid,平均人群疾病年龄66岁。
  • 血浆Aβ42/40平均比Aβ-PET异常早约2年。
  • APOE ε4携带者与非携带者Centiloid异常年龄差异约7年。
  • 两种检测均显示Aβ-PET水平大于约14 Centiloid时血浆Aβ42/40降至稳态。

临床怎么用

  • 血浆Aβ42/40可作为阿尔茨海默病临床前阶段早期筛查和动态监测的血液标志物。
  • 解读血浆Aβ42/40结果时应结合APOE ε4携带状态,因其异常年龄和对应Centiloid阈值不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sporadic late-onset Alzheimer's disease (AD) is characterized by a long pre-clinical phase where amyloid-beta (Aβ) and tau begin to accumulate in the brain. The primary objective was to determine the age at which AD starts by finding the average population age when both positron emission tomography (PET) Aβ (Aβ-PET) and plasma Aβ42/40 become abnormal. METHODS: Two high performance immunoprecipitation-mass spectrometry (IP-MS) assays (WashU/C2N and Shimadzu) were tested on samples from 1,450 participants who were diagnosed as cognitively unimpaired (CU), mild cognitive impairment (MCI), or AD-dementia across 4 international cohorts. Natural history modeling and trajectory analyses of the combined Aβ-PET and plasma Aβ42/40 data were analyzed. RESULTS: Data from both assays demonstrated Aβ42/40 undergoes a rapid change at approximately 15 Centiloid (CL), at an average population disease age at 66 years. On average, plasma Aβ42/40 becomes abnormal approximately 2 years before Aβ-PET, whereby it falls sharply to a stable level at the onset of preclinical AD. Average disease age where Aβ42/40 becomes abnormal, and the corresponding Centiloid level are lower for APOE allele carriers compared with non-carriers. INTERPRETATION: Plasma Aβ42/40 ratio presents a step-like function of peripheral change shortly before the detection of plaques by Aβ-PET. Results are consistent with plasma Aβ42/40 falling to a steady-state level in participants with Aβ-PET levels greater than approximately 14CL for both assays. The age at which this occurs is dependent on APOE ε4 carriership, consistent with the approximate 7-year age difference in Centiloid abnormality between carriers and non-carriers. ANN NEUROL 2026;99:1327-1342.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Cánovas R, Cox T, Doré V, et al. When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 Years. Ann Neurol. 2026. PMID: 41586468. doi:10.1002/ana.78163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。